Wandercraft Gains Second FDA Indication Extension for Atalante X in Less Than Two Years, Extending Advanced Robotic Rehabilitation for More Patients with Severe Mobility Loss

The extension of indication authorizes use in individuals with spinal cord injury (SCI) from levels C4 to L5 and in those with multiple sclerosis (MS), broadening access to upright, hands-free gait ...